Overall, SGLT2 inhibitors have demonstrated significant reductions in cardiovascular adverse events, including cardiovascular death, hospitalizations for HF, and major adverse cardiovascular events, across different patient populations and risk profiles. Here, SLC5A2 is linked to hydrops fetalis.